The bottom line on side effects: Retatrutide is not dramatically riskier for most people, but it is not a simple lateral move
Store refrigerated at 28C
Zepbound is covered under the GLP-1 Bridge, but only the KwikPen formulation
It is precisely this superiority at weight loss that is also the root of the higher hair-loss risk
Third, oral semaglutide (Wegovy pill, $149/mo at Walgreens) entered US distribution in late 2025, giving needle-averse patients a brand-name option for the first time
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority